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Summary Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this
disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m-2 day-1 on days
1-3) and cisplatin (100 mg m-2 day-1 on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A
complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour
response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as
shown by serum levels >14 mg 1-'. Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.
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Adrenocortical carcinoma (ACC) is a rare malignant tumour with
a poor prognosis (Hutter and Kayhoe, 1966; Bertagna and Orth,
1981; Didolkar et al 1981; Luton et al, 1990). An aggressive
surgical approach provides disease control for the minority of
patients presenting with localized disease. In patients with
advanced disease, survival is < 50% at I year and < 10% at 5 years
(Luton et al, 1990; Jensen et al, 1991; Icard et al, 1992; Pommier
and Brennan, 1992).
Mitotane has been associated with control ofhormonal produc-
tion, regression of metastases or even cure in selected patients
with metastatic disease (Hutter and Kayhoe, 1966; Boven et al,
1984). The routine measurement of its serum level permits an
effective dosage to be given, when it is above 14 mg 1- (Haak et
al, 1994). In Haak et al's retrospective study, a tumour response
was observed in 55% with serum mitotane above 14 mg 1- and in
none of those with a mitotane serum level below 14 mg 1-'. Side-
effects may be avoided by maintaining serum mitotane level
below 20 mg 1'.
Cisplatin is the most widely tested cytotoxic agent in this
disease. Used alone, it provides a response rate around 30%. Its
combination with mitotane did not increase the response rate
(Tattersall et al, 1980; Chun et al, 1983; Bukowski et al, 1993).
Combination with other cytotoxic agents has been reported in two
studies with response rates similar to that obtained with cisplatin
alone. The combination of 5-fluorouracil, doxorubicin and
cisplatin produced one complete (CR) and two partial responses
(PRs) in 13 patients (Schlumberger et al, 1991). The combination
of cyclophosphamide, doxorubicin and cisplatin produced two
PRs in 11 patients (Van Slooten and Van Oosterom, 1983).
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Preliminary reports of the combination of cisplatin with etopo-
side (VP16) were encouraging (Johnson and Greco, 1986; Hesketh
et al, 1987; Burgess et al, 1993). This led us to use it in 18 patients
with progressing AAC.
PATIENTS AND METHODS
Eligibility criteria
Between 1993 and 1997, 18 patients with progressive metastatic or
residual ACC in whom complete surgical removal of disease was
not possible were entered into the study. All patients were treated
with mitotane at the time of inclusion. Measurement of serum
mitotane level has been available since 1996; serum mitotane level
was above 14 mg 1-1 in six of the nine patients in whom it was
measured. Mitotane (Pharmacie Centrale de l'Assistance
Publique-Hopitaux de Paris) was given by mouth as capsules
containing 0.5 g of micronized mitotane mixed with cellulose
acetylphthalate (Luton et al, 1990). This provides a good digestive
tolerance but a low bioavailability. The mean initial dose was 10 g
per day, and the maintenance dose ranged from 3 to 9 g.
Additional criteria included: objectively measurable disease, a
World Health Organization (WHO) performance status of 0-2,
adequate bone marrow function (defined as leucocyte count
> 4000 mm-3 and platelet count > 100 000 mm-3), normal liver
function (bilirubin level <26 gM) and normal renal function
(serum creatinine < 110 IM).
Baseline X-rays, bone scan, abdominal ultrasonography,
computerized tomography (CT) scans of the abdomen and the
chest were obtained.
The biochemical profile included urinary excretion of
17-hydroxycorticosteroids and 17-ketosteroids, serum and
urinary cortisol, plasma 17-hydroxyprogesterone, 11-desoxycor-
tisol, 11-desoxycorticosterone, aldosterone, and oestradiol-17f.
This study was performed according to the ethical rules of our
institution.
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Treatment
Chemotherapeutic agents were administered i.v. every 4 weeks:
etoposide (VP16) (100 mg m-2day-') on days 1-3 and cisplatin at
a dose of 100 mg m-2 day-' on day 1, with hydration and mannitol
diuresis on day 2.
Mitotane treatment was maintained at the same dosage during
chemotherapy in 14 patients.
Evaluation of response and toxicity
Patients underwent a clinical evaluation with full blood count
biochemistry and chest radiographs, before each course of
chemotherapy. Other imaging modalities, e.g. ultrasonography of
the abdomen, bone scan, CT scans or magnetic resonance imaging
(MRI) were performed again after three and six courses of
chemotherapy, and ifprogressive disease was suspected.
Objective responses were classified according to WHO criteria.
A CR was defined as the disappearance of all measurable lesions
and no new lesions for at least 4 weeks. A PR was defined as a
reduction of at least 50% in the sum of the products of the longest
perpendicular diameters of all measurable lesions and the absence
of new lesions for at least 4 weeks. Stable disease (SD) was
defined as a reduction of less than 50% or an increase of less than
25% in the sum of the products of the perpendicular diameters of
all lesions without any evidence of new lesions for at least 4
weeks. Progressive disease (PD) was defined as an increase
greater than 25% in tumour size or the appearance ofnew lesions.
Response durations were measured as the interval from initial
response attainment to the time ofunequivocal disease progression.
The patients were observed longitudinally until evidence of
progressive disease or toxicity appeared, at which time therapy
was discontinued.
The WHO criteria were used to report toxicity.
RESULTS
Patients
Patient characteristics are shown inTable 1. Median age was 46 ± 16
years (range 22-69); there were 11 female and seven male patients.
Ofthe 18 patients, 13 patients had multiple site involvement; seven
patients had an adrenal mass; 16 patients had metastases, 13 in
lungs, nine in the liver, five in bones, one in the thyroid, and five in
lymph nodes, including two in abdominal and three in mediastinal
lymph nodes. Ten patients had a hormonally active adrenal carci-
noma: elevated production ofcortisol was detected in four patients,
ofcortisol and androgens in fourpatients, ofcortisol and aldosterone
in one patient and of oestrogens in one patient. All patients had
received prior treatment with mitotane for 1-22 months, and tumour
progression occurred during this treatment. However, mitotane treat-
ment was maintained in 14 patients at the same dosage (3-9 g day-')
during chemotherapy in view of its possible antihormonal effects
and also of its possible synergistic effects with chemotherapy.
Mitotane therapy was discontinued in four patients because side-
effects were prominent (nausea, emesis, somnolence and fatigue).
Tumour response
All 18 patients entered into this study were evaluated for response.
CR was observed in three cases and PR in three cases, giving an
overall response rate of33%.
Patient 1, with an adrenal mass and abdominal lymph nodes,
had a CR that lasted for more than 26 months. Patient 4, with
lung metastases and a hormonally active adrenal carcinoma, had
a CR for 15 months. Thereafter, lung metastases reappeared and
caused death. Patient 7, with an adrenal mass, had a CR for 11
months. At that time, lung metastases were discovered. Patient 3,
with lung and liver metastases, had a PR for 9 months. At that
time, progression of liver metastases occurred. Patient 5, with
multiple site involvement, had a PR for 11 months. Patient 17,
with lung and liver metastases, had a PR for more than 9 months.
Two patients (nos 12 and 16) were classified as stabilized. Ten
patients had PD including one patient (patient 15) who died after
the second course of chemotherapy because of rapid disease
progression.
Tumour response was observed in three of the six with PD
during treatment with mitotane given at an effective dosage, as
shown by serum level > 14 mg 1-l.
Toxicity
Nausea and vomiting occurred in all patients; myelosuppression
occurred in seven patients (grade 2 in three, grade 3 in three and
grade 4 in one). Neurological effects occurred in one patient after
three courses. Nephrotoxicity was not observed, despite previous
nephrectomy in five patients.
No patient required discontinuation oftherapy for toxicity.
DISCUSSION
Information on the efficacy of cytotoxic chemotherapy in ACC is
limited, primarily because ofthe rarity ofthe disease.
Mitotane appeared to control endocrine hypersecretion effec-
tively in 75% ofpatients and provides an objective response rate
in a noticeable proportion of patients (14-38%) with minimal
side-effects in some series (Lubitz et al, 1974; Bertagna and
Orth, 1981; Boven et al, 1984; Luton et al, 1990). A high
percentage of tumour responses have been partial and transient,
but some CRs lasting a few years have been reported (Boven
et al, 1984). In a retrospective study, the only prognostic factor
for response to mitotane appeared to be its serum level (Haak
et al, 1994).
In cases of tumour progression during mitotane treatment, a
cytotoxic chemotherapy regimen is warranted. The association of
cisplatin and etoposide (VP16) every 3-4 weeks is considered to
be the reference combination at the present time. This combination
proved to be effective in two trials with eight PRs
in 15 patients (overall rate 53%) (Johnson and Greco, 1986;
Burgess et al, 1993).
In our series of 18 patients, an objective response was
observed in six patients, including three CRs (26 +, 15 and 11
months) and three PRs (11, 9+ and 9 months). The overall
response rate was 33% and is not significantly different from that
obtained with cisplatin alone or in combination with other cyto-
toxic agents. The toxicity of this combination was noticeable but
acceptable. Ofnote, its combination with mitotane did not appear
to be synergistic.
A tumour response was observed in three of the six patients
treated with mitotane given at an effective dosage (serum level
> 14 mg 1-'); this observation suggests the absence of cross-
resistance between the two therapeutic regimens.
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In conclusion, in patients with metastatic ACC, mitotane may
be given as initial treatment, monitoring its serum level allows an
effective dosage to be given, while avoiding side-effects. In cases
ofprogression during mitotane treatment, cytotoxic chemotherapy
is indicated and mitotane treatment should be discontinued in
those patients with non-functioning ACC. At the present time, the
combination of etoposide and cisplatin appears to be the standard.
However, a relatively low response rate and the short duration of
most responses strongly suggest that othertherapeutic trials should
be performed in patients with advanced ACC, using other cyto-
toxic drugs.
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